Background and purpose: Positive inotropic responses (PIR) to 5-hydroxytryptamine (5-HT) are induced in the left ventricle (LV) in rats with congestive heart failure (CHF); this is associated with upregulation of the G s -coupled 5-HT 4 receptor. We investigated whether chronic 5-HT 4 receptor blockade improved cardiac function in CHF rats. Experimental approach: Rats were given either the 5-HT 4 antagonist SB207266 (0.5 mg kg À1 24h À1 ; MI int ) or placebo (MI pl ) through mini-osmotic pumps for 6 weeks subsequent to induction of post-infarction CHF. In vivo cardiac function and ex vivo responses to isoprenaline or 5-HT were evaluated using echocardiography and isolated LV papillary muscles, respectively. mRNA levels were investigated using real-time quantitative RT-PCR. Key results: LV diastolic function improved, with 4.6% lower LV diastolic diameter and 24.2% lower mitral flow deceleration in MI int compared to MI pl . SB207266 reduced LV systolic diameter by 6.1%, heart weight by 10.2% and lung weight by 13.1%. The changes in posterior wall thickening and shortening velocity, cardiac output, LV systolic pressure and (dP/dt) max , parameters of LV systolic function, did not reach statistical significance. The PIR to isoprenaline (10 mM) increased by 36% and the response to 5-HT (10 mM) decreased by 57% in MI int compared to MI pl . mRNA levels for ANP, 5-HT 4(b) and 5-HT 2A receptors, MHCb, and the MHCb/MHCa -ratio were not significantly changed in MI int compared to MI pl . Keywords: 5-HT; congestive heart failure; 5-HT 4 receptor blockade; SB207266; piboserod Abbreviations: CHF, congestive heart failure; CO, cardiac output; CRC, contraction relaxation cycles; (dP/dt) max , (dP/dt) min maximum and minimum derivative of the pressure curves; (dF/dt) max , maximal development of force; FS, fractional shortening; LAD, left atrial diameter; LV, left ventricle; LVDd, LV diameter in diastole; LVDs, LV diameter in systole; LVEDP, LV end diastolic pressure; MI, myocardial infarction; MI int , MI intervention; MI pl , MI placebo; PIR, positive inotropic response; Polr2A, polymerase (RNA) II (DNA directed) polypeptide A; PW, posterior wall; PWSV, PW shortening velocity; RT, time from peak force to 80% relaxation; RT-PCR, real-time reverse transcriptase-polymerase chain reaction; SBP, systolic blood pressure; TBP, TATA box binding protein; TPF, time to peak force
Conclusions and implications: